arrow
E

Evaristo Maiello

casa sollievo della sofferenza
H指数:55
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Parente et al. Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience. Diagnostics 2022, 12, 685

修正:Parente等人. 接受ICI治疗并出现胃肠道毒性的患者的临床、内镜和组织学特征:来自单一机构经验的最新消息和重新评估。Diagnostics 2022, 12, 685

2026-07-290
OA
The impact of PROgnostic SIgnatures in stage II colon cancer patients enrolled in the phase III clinical trial TOSCA: the PROSIT study

II期结直肠癌患者中预后特征的影响:PROSIT研究(TOSCA III期临床试验)

2026-01-010
OAAI
HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI

HER-2基因改变作为接受FOLFIRI治疗的转移性结直肠癌患者的生物标志物

2026-01-010
OA
Comparative Analysis of Fecal Microbiota in Healthy Controls and Pancreatic Cancer Patients: A Focus on Tumor Localization Differences in Pancreatic Head and Body-Tail

健康对照组与胰腺癌患者粪便微生物群的比较分析:重点关注胰腺头部分与体尾部肿瘤定位差异

2025-12-120
OAAI
Comprehensive Molecular Screening by Next Generation Sequencing of Gastrointestinal Stromal Tumors (GISTs): In Silico Analysis and Classification of Rare KIT Exon 11 Mutations

下一代测序技术对胃肠道间质瘤(GISTs)的全面分子筛查:基于计算机的分析和罕见KIT外显子11突变的分类

2025-12-080
OAAI
Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy

微卫星稳定型结直肠癌中高肿瘤突变负荷的基因组分析揭示了抗-EGFR治疗后MAPK信号通路的改变

2025-10-280
OAAI
Development of a microRNA-based prognostic model for accurate prediction of distant metastasis in breast cancer patients

基于microRNA的预后模型开发,用于准确预测乳腺癌患者的远处转移

2025-10-030
OAAI
Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial

液体活检综合基因组分析描绘了转移性结直肠癌的突变景观,以预测CAPRI-2 GOIM试验中FOLFIRI联合西妥昔单抗的抗肿瘤疗效。

2025-04-010
PRE
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial
2024-12-011
PRE
Tumor Suppressor miR-27a-5p and Its Significance for Breast Cancer
2024-11-170
OAAI
A powerful machine learning approach to identify interactions of differentially abundant gut microbial subsets in patients with metastatic and non-metastatic pancreatic cancer
2024-07-073
OAAI
Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial

在未经治疗的HER2阴性晚期乳腺癌中,比较含节拍蒽环类药物的化疗与标准方案的II期随机试验: GOIM 21003试验的活性和生活质量结果

BREAST
IF7.9
2024-06-010
OAAI
Prognostic genomic signatures in RAS/BRAF mutant (mut) metastatic colorectal cancer (mCRC) patients (pts) from the phase II study of NIVolumab (niv) plus FOLFOXIRI/Bevacizumab (bev) in first-line therapy of Advanced COloRectal cancer (NIVACOR- GOIRC-03-2018)
2024-06-010
PRE